GBI Research's report "Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies" finds that the global herpes market is an attractive one, and is expected to witness growth during the forecast period and to provide good opportunities for investors. The expected high growth is attributed to increasing awareness regarding herpes infections and a growth in the diseased population. Many promising therapies, especially for Cytomegalovirus (CMV) infections, are expected to launch during the forecast period. The market is currently generic in nature, with few first-in-class molecules. The current therapies provide only symptomatic treatment of infections, meaning that infection can lay dormant in patients, recurring in the future. This is unmet need of the market, which needs to be resolved.

The value of the global herpes market (herpes simplex, herpes zoster and Cytomegalovirus infections) is estimated to have been approximately $4.2 billion in 2010, and this figure is expected to grow at a CAGR of 10.1% to reach $9.1 billion by 2018. The market has limited scope for growth due to the heavy presence of generic products and the lack of innovation in the pipeline products. The current treatment options serve the markets needs, providing symptomatic treatment for herpes simplex and herpes zoster infections. There is current unmet need in the market for safer therapeutics, particularly for CMV infections. There are nine molecules in Phase III of clinical development for various herpes infections. The diseased population is expected to reach approximately 158.6 million by 2018, driven by immunosuppressed patients and transplant recipients.

GBI Research finds that the competition in the global herpes therapeutics market is strong, with the presence of four primary marketed drugs and many generic brands. The total viral therapeutics market is forecast to grow at a high rate until 2018. The emergence of novel therapies concentrating on increasing drug safety and increasing patient awareness and compliance are major factors that will contribute to the growth of this market. Since the market is genericized, there are numerous small tier companies manufacturing therapeutic drugs. However, the tier one manufacturers such as GlaxoSmithKline and Novartis will continue to dominate the market due to their extensive marketing and licensing strategies.

The herpes therapeutics market (herpes simplex and herpes zoster) was valued at $3.6 billion in 2010. The market grew at a CAGR of 14.2%, from $1.6 billion in 2004 to $3.6 billion in 2010. The primary objectives of the available therapies are the suppression and treatment of the symptoms of the disease. Drugs such as antivirals, analgesics.

Scope

• The report analyses the treatment patterns, market characterization, pipeline, competitive landscape and key merger and acquisition trends in the global herpes infection market.
• Data and analysis on the global herpes infection market.
• Market forecasts for the global herpes infection market until 2018.
• Market Data on the geographical landscape including country wise coverage, cost of therapy, market size and market share.
• Key drivers and restraints that have created a significant impact on the market.
• Competitive landscape of the global herpes infection market including top companies profiles. The key companies studied in this report are GlaxoSmithKline, Merck, Novartis and Roche.
• Key M&A activities and licensing agreements that have taken place between 2007 and 2011 in the global herpes infection market.

Reasons to buy

• The information in the report will aid business development and help marketing executives to build effective strategies to launch their pipeline products by identifying potential geographies. 
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill others portfolio gaps. 
• Develop key strategic initiatives by studying the key strategies of top competitors. 
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. 
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class therapies with more efficacy and better safety.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

List of Tables

Table 1: Herpes Market, Global, Revenues ($bn), 2004-2010 10
Table 2: Herpes Market, Global, Revenue Forecasts ($bn), 2010-2018 10
Table 3: Herpes Market, Global, Annual Cost of Treatment ($), 2004-2010 11
Table 4: Herpes Market, Global, Annual Cost of Treatment ($), 2010-2018 11
Table 5: Herpes Market, Global, Treatment Usage Pattern (millions), 2004-2010 12
Table 6: Herpes Market, Global, Treatment Usage Pattern (millions), 2010-2018 12
Table 7: Herpes Therapeutics Market, Global, Revenues by Geography ($m), 2004-2010 14
Table 8: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010-2018 15
Table 9: Herpes Market, The US, Revenues ($m), 2004-2010 16
Table 10: Herpes Market, The US, Revenue Forecasts ($m), 2010-2018 16
Table 11: Herpes Market, The US, Treatment Usage Pattern (millions), 2004-2010 17
Table 12: Herpes Market, The US, Treatment Usage Pattern (millions), 2010-2018 18
Table 13: Herpes Market, Top Five Countries of Europe, Revenues ($m), 2004-2010 19
Table 14: Herpes Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2018 19
Table 15: Herpes Market, Top Five Countries of Europe, Revenues ($m), 2004-2010 20
Table 16: Herpes Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2018 21
Table 17: Herpes Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004-2010 22
Table 18: Herpes Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010-2018 23
Table 19: Herpes Market, Japan, Revenues ($m), 2004-2010 24
Table 20: Herpes Market, Japan, Revenue Forecasts ($m), 2010-2018 24
Table 21: Herpes Market, Japan, Treatment Usage Pattern (millions), 2004-2010 25
Table 22: Herpes Market, Japan, Treatment Usage Pattern (millions), 2010-2018 25
Table 23: Herpes Therapeutics Market, Global, Revenues ($bn), 2004-2010 29
Table 24: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 29
Table 25: Herpes Therapeutics Market, Global, Revenues by Geography ($m), 2004-2010 30
Table 26: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010-2018 31
Table 27: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 33
Table 28: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 33
Table 29: Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004-2010 34
Table 30: Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2018 35
Table 31: Cytomegalovirus Therapeutics Market, Global, Revenues ($m), 2004-2010 38
Table 32: Cytomegalovirus Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 38
Table 33: Cytomegalovirus Therapeutics Market ,Global, Revenues by Geography ($m), 2004-2010 39
Table 34: Cytomegalovirus Therapeutics Market ,Global, Revenue Forecasts by Geography ($m), 2010-2018 40
Table 35: Cytomegalovirus Therapeutics Market , Global, Annual Cost of Treatment ($), 2004-2010 42
Table 36: Cytomegalovirus Therapeutics Market , Global, Annual Cost of Treatment ($), 2010-2018 42
Table 37: Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern (000), 2004-2010 43
Table 38: Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern (000), 2010-2018 44
Table 39: Herpes Simplex Market, Global, R&D Pipeline by Phase, September 2011 48
Table 40: Herpes Zoster Market, Global, R&D Pipeline by Phase, September 2011 49
Table 41: Cytomegalovirus Therapeutics Market, Global, R&D Pipeline by Phase, September 2011 51
Table 42: Herpes Market, Global, Deals by Type of Agreement, 2007-2011 62
Table 43: Herpes Market, Global, Deals by Geography, 2007-2011 64

List of Figures

Figure 1: Herpes Market, Global, Revenue Forecasts ($bn), 2004-2018 10
Figure 2: Herpes Market, Global, Annual Cost of Treatment ($), 2004-2018 11
Figure 3: Herpes Market, Global, Treatment Usage Pattern (millions), 2004-2018 12
Figure 4: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2004-2018 14
Figure 5: Herpes Market, The US, Revenue Forecasts ($m), 2004-2018 16
Figure 6: Herpes Market, The US, Treatment Usage Pattern (millions), 2004-2018 17
Figure 7: Herpes Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2004-2018 19
Figure 8: Herpes Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2004-2018 20
Figure 9: Herpes Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004-2018 22
Figure 10: Herpes Market, Japan, Revenue Forecasts ($m), 2004-2018 24
Figure 11: Herpes Market, Japan, Treatment Usage Pattern (millions), 2004-2018 25
Figure 12: Herpes Therapeutics Market, Global, Treatment Algorithm 28
Figure 13: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 29
Figure 14: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2004-2018 30
Figure 15: Herpes Therapeutics Market, Global, Branded and Generic Market Share(%), 2010 and 2018 32
Figure 16: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 33
Figure 17: Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004-2018 34
Figure 18: Herpes Therapeutics Market, Drivers and Barriers, 2010-2018 36
Figure 19: Cytomegalovirus Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 38
Figure 20: Cytomegalovirus Therapeutics Market ,Global, Revenue Forecasts by Geography ($m), 2004-2018 39
Figure 21: Cytomegalovirus Therapeutics Market ,Global, Branded and Generic Market Share (%), 2010 and 2018 41
Figure 22: Cytomegalovirus Therapeutics Market , Global, Annual Cost of Treatment ($), 2004-2018 42
Figure 23: Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern (000), 2004-2018 43
Figure 24: Herpes Market, Global, R&D Pipeline by Indication (%), September 2011 46
Figure 25: Herpes Simplex Market, Global, R&D Pipeline by Phase (%), September 2011 47
Figure 26: Herpes Zoster Market, Global, R&D Pipeline by Phase (%), September 2011 49
Figure 27: Cytomegalovirus Therapeutics Market, Global, R&D Pipeline by Phase (%), September 2011 50
Figure 28: Herpes Market, Global, Competitive Landscape, GlaxoSmithKline, SWOT, 2011 58
Figure 29: Herpes Market, Global, Competitive Landscape, Novartis, SWOT, 2011 59
Figure 30: Herpes Market, Global, Competitive Landscape, Merck, SWOT, 2011 60
Figure 31: Herpes Market, Global, Competitive Landscape, Roche, SWOT, 2011 61
Figure 32: Herpes Market, Global, Deals by Type of Agreement (%), 2007-2011 62
Figure 33: Herpes Market, Global, Deals by Year, 2007-2011 63
Figure 34: Herpes Market, Global, Deals by Geography, (%), 2007-2011 64
Figure 35: GBI Research Market Forecasting Model 70